Skip to main content
. 2020 Jan 6;37(2):25. doi: 10.1007/s11095-019-2752-y

Fig. 7.

Fig. 7

ACR20, ACR50, and ACR70 simulation for fenebrutinib (GDC-0853), adalimumab, and tofacitinib treatments in TNF-inhibitor-naïve Population. TNF, tumor necrosis factor; MTX, methotrexate; bid, twice daily; q2w, once every two weeks. Bands: 90% prediction interval; blue middle line: median prediction.